KIN1408 | CAS#1903800-11-2

MedKoo Cat#: 525443 | Name: KIN1408

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

KIN1408 is an inducer of cellular transcription of innate immune genes in a MAVS- and IRF3-dependent manner, exhibiting broad-spectrum anti-viral activity.

Chemical Structure

KIN1408

CAS#1903800-11-2

Theoretical Analysis

MedKoo Cat#: 525443

Name: KIN1408

CAS#: 1903800-11-2

Chemical Formula: C25H19F2N3O3S

Exact Mass: 479.1115

Molecular Weight: 479.50

Elemental Analysis: C, 62.62; H, 3.99; F, 7.92; N, 8.76; O, 10.01; S, 6.69

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 350.00	2 Weeks
25mg	USD 650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

KIN1408

IUPAC/Chemical Name

7-((4-(Difluoromethoxy)phenyl)(5-methoxybenzo[d]thiazol-2-ylamino)methyl)quinolin-8-ol

InChi Key

YSGBFDHVEQJPPX-UHFFFAOYSA-N

InChi Code

InChI=1S/C25H19F2N3O3S/c1-32-17-9-11-20-19(13-17)29-25(34-20)30-21(15-4-7-16(8-5-15)33-24(26)27)18-10-6-14-3-2-12-28-22(14)23(18)31/h2-13,21,24,31H,1H3,(H,29,30)

SMILES Code

OC1=C2N=CC=CC2=CC=C1C(C3=CC=C(OC(F)F)C=C3)NC4=NC5=CC(OC)=CC=C5S4

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

KIN1408 is an agonist of the RIG-1-like receptor (RLR) pathway and exhibits a broad-spectrum antiviral activity.

In vitro activity:

Treatment of cells with 5 μM KIN1408 was sufficient to cause a 1.5-log-unit decrease in the number of infectious virus particles compared to that achieved with treatment with DMSO at 96 h postinfection (Fig. 7C). Reference: J Virol. 2015 Dec 16;90(5):2372-87. https://pubmed.ncbi.nlm.nih.gov/26676770/

In vivo activity:

TBD

	Solvent	mg/mL	mM
Solubility
	DMSO	34.5	71.95

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 479.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Pattabhi S, Wilkins CR, Dong R, Knoll ML, Posakony J, Kaiser S, Mire CE, Wang ML, Ireton RC, Geisbert TW, Bedard KM, Iadonato SP, Loo YM, Gale M Jr. Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR Pathway. J Virol. 2015 Dec 16;90(5):2372-87. doi: 10.1128/JVI.02202-15. PMID: 26676770; PMCID: PMC4810700.

In vitro protocol:

In vivo protocol:

TBD